Breaking News
0

Incyte Corporation (INCY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Incyte's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
87.27 +1.13    +1.31%
11:51:30 - Real-time Cboe. Currency in USD ( Disclaimer )
Type: Equity
Market: United States
ISIN: US45337C1027 
CUSIP: 45337C102
  • Volume: 175,149
  • Bid/Ask: 87.25 / 87.35
  • Day's Range: 85.13 - 87.27
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider
Incyte 87.27 +1.13 +1.31%
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider

INCY Overview

 
This is the main Incyte Corporation stock chart and current price. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close86.14
Day's Range85.13 - 87.27
Revenue2.11B
Open85.95
52 wk Range57 - 89.3
EPS1.86
Volume175,149
Market Cap18.77B
Dividend (Yield)N/A (N/A)
Average Vol. (3m)1,065,681
P/E Ratio45.52
Beta0.95
1-Year Change37.03%
Shares Outstanding215,397,290
Next Earnings DateFeb 14, 2020
What is your sentiment on Incyte?
or
Vote to see community's results!

Incyte Corporation News


Incyte Corporation Analysis


Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Buy Buy Buy Buy Buy
Technical Indicators Strong Buy Strong Buy Strong Buy Strong Buy Strong Buy
Summary Strong Buy Strong Buy Strong Buy Strong Buy Strong Buy

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Harami Bearish 30 Current
Three Outside Up 1M Current
Completed Patterns
Bullish Engulfing 1M 1 Oct 19
Three Outside Up 1H 1 Nov 13, 2019 10:00AM
Bullish Engulfing 1H 2 Nov 13, 2019 09:00AM

Incyte Corporation Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 87.27 87.25 87.35 175,149 +1.31% USD 11:51:30  
  Berlin 79.07 78.70 79.34 0 +1.04% EUR 11:12:00  
  Stuttgart 78.26 69.66 70.65 310 0.00% EUR 12/11  
  Munich 78.78 78.96 79.09 0 +0.95% EUR 10:25:00  
  Vienna 78.260 0.000 0.000 0 0.00% EUR 12/11  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 264.01 264.17 261.07 +2.01 +0.77% 10.93M 11:51:38  
  Facebook 193.38 195.69 192.87 -1.08 -0.56% 5.39M 11:51:16  
  AMD 37.87 37.96 36.58 +1.17 +3.17% 38.96M 11:51:37  
  Alphabet A 1,300.70 1,302.30 1,293.32 +3.20 +0.25% 275.70K 11:51:07  
  Tesla 350.52 356.33 349.09 +0.57 +0.16% 5.05M 11:50:38  
  Amazon.com 1,766.30 1,774.92 1,759.57 -12.03 -0.68% 1.04M 11:51:37  
  Microsoft 147.10 147.46 146.30 -0.01 -0.01% 6.23M 11:51:33  
  Alibaba ADR 182.03 185.66 181.13 -4.94 -2.64% 8.41M 11:51:37  
  IBM 134.42 135.55 133.95 -1.19 -0.88% 927.20K 11:51:35  
  FuelCell Energy 0.839 0.900 0.599 +0.291 +53.17% 97.13M 11:51:39  

Incyte Corporation Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

1367

Equity Type

ORD

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
Securities Investor Protection Corporation (United States) $0 Start Trading
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) $0 Start Trading
National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States) $500 Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

INCY Comments

Write your thoughts about Incyte Corporation
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ronda Zelman
Ronda Zelman Jul 07, 2018 6:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is why the stock lost 44% for the year? Who said $175?
Leonid Agureev
Leonid Agureev Apr 08, 2018 6:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
goes to 50...hmm
Giacomo Carducci
Giacomo Carducci Feb 13, 2018 6:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock is conservatively worth $105. I wouldn't be surprised if its closer to $175 than $100 by the end of the yr.
Giacomo Carducci
Giacomo Carducci Feb 13, 2018 6:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Also, one of the finest stock research letters (Oxford Communique) loved it at $100 and deemed it one of their Ten-Bagger portfolio stocks. The Oxford Club knows what they're talking about too.
Tyler Baker
Tyler Baker Feb 13, 2018 6:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yeah, totally.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email